As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Products
Research Products
Amino Acids Bile Acids Biochemical Pathways Biological Standards Buffers and Reagents Carbohydrates CellFree Protein Expression Cell Growth Media Chemical Tagging Reagents Deuterated Reagents for ElectronicsDeuterated Reagents for PharmaceuticalsElements and Compounds Fatty Acids & Lipids Drug Standards Gases cGMP ProductsGlycans IROA Biochemical Quantitation Kits Key Metabolite Standards a-Keto Acids13C Metabolic Probes Metabolomics Mixes and Kits Metabolites & Substrates Methyl Labeling Kits & Amino Acids		 Metabolomics & Cellular 
MetabolismMicrobiological & Pyrogen Tested Mouse Express® Mouse Feed MRI/MRS Products MRM PeptiQuant™ Assay Kits MS/MS StandardsNMR Solvents and ConsumablesNucleic AcidsOrganic Acids & Conjugate Salts Protein StandardsProtein Reagents15N SaltsSILAC ReagentsSpirulinaSteroids and HormonesSynthetic IntermediatesVitaminsWater		 Environmental Contaminant Standards
Cyanotoxin Standards
Dioxin & Furan Individual Standards Dioxin & Furan Method Standards, Standard Mixtures, and Reference Materials PCB Standards & Standard MixturesFlame Retardants Dioxin/Furan Plus PCB Standard Mixtures Polycyclic Aromatic Hydrocarbon (PAH) Standards and Standard Mixtures Priority Pollutant Standard Mixtures Priority Pollutant, Endocrine Disruptor, and Chemical Contaminant Standards
Pesticides, Herbicides, and Metabolites Standards PPCPs Phthalate & Phthalate Metabolite Standards Chemical Weapon Metabolite Standards Per- and Polyfluoroalkyl Substances (PFAS)Stockholm Treaty Compounds

 

New Products

Corporate Overview


In the News – Food and Drug Administration (FDA) Approves the First Deuterated Drug, AUSTEDO™ by Teva

April 26, 2017
Cambridge Isotope Laboratories, Inc. is pleased that the Food and Drug Administration (FDA) has approved the first deuterated drug, AUSTEDO™ by Teva (previously referred to as SD-809). This deuterated drug was developed for the treatment of chorea, random involuntary twisting movements, which is associated with Huntington’s disease. This newly developed deuterated drug will not only reduce these symptoms but will help improve the quality of life of the tens of thousands of patients and the families of those suffering from HD. CIL congratulates Teva on this ground-breaking accomplishment. As a the long-term deuterium supplier worldwide, CIL looks forward to serving the pharmaceutical industry as it advances in improved drug development and remains committed to improving the quality of life of others.


Link to TEVA Press Release.
 
 
Back to list

News Index

CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.